Communiqués FibroBiologics, Inc.

Actions

FBLG

US31573L2043

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
0,7000 ^USD	-2,67%		-1,69%	-84,44%

31/07	FibroBiologics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
09/07	FibroBiologics, Inc. annonce la nomination de Kathleen " Kate » Rubins à son conseil d'administration	CI

Communiqués

31/07	FibroBiologics : Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate	PU
07/07	FibroBiologics : Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial	PU
30/06	FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference	PR
29/06	FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	PR
26/06	FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	PR
22/06	FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing	AQ
16/06	FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers	AQ
03/06	FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers	AQ
22/05	FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting	AQ
18/05	FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics	AQ
11/05	FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus	AQ
05/05	FibroBiologics CEO Issues Letter to Shareholders	AQ
04/05	FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring	AQ
04/05	FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial	AQ
01/05	FibroBiologics : Reports Q1 2026 Financial Results and Provides Corporate Update	PU
30/04	FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update	AQ
30/04	FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026	AQ
20/04	FibroBiologics Compliant with All Nasdaq Listing Requirements	AQ
10/04	FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity	AQ
02/04	FibroBiologics Announces Closing of $3 Million Public Offering	AQ
01/04	FibroBiologics Announces Pricing of $3 Million Public Offering	AQ
31/03	FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial	AQ
25/03	FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement	GL
12/03	FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology	GL
05/03	FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers	GL